iShares Biotechnology ETF

IBB

Market cap $8.6B

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.

The biotech sector, represented by the iShares Biotechnology ETF, has experienced a notable rally in recent months. The key driver of the 40% over the past six months has been a notable uptick in M&A volume, with another major buyout last week. Even with the huge recent rise in the biotech sector, it still trades below its level of four years ago and could go still higher if M&A volume remains elevated.

Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.

The 'Fast Money' traders talk how to play biopharma space.

Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Acquired 77,000 shares, valued at $11.1 million Transaction represents 8.7% of 13F reportable AUM Post-trade position: 77,000 shares valued at $11.1 million IBB is now the fund's 2nd-largest holding, accounting for 8.7% of AUM

While many investors focus on semiconductors and AI or the growth sector, one of my Economic Modern Family members has been busy. The Biotech Sector ETF (NASDAQ: IBB), has made new multi-year highs.

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to date, IBB has risen 18.2% versus SPY's 17.2% gain.

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.